Oxford Biomedica PLC Initiation of Second CART Programme for Novartis (3770N)
January 29 2016 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 3770N
Oxford Biomedica PLC
29 January 2016
Oxford BioMedica Announces Initiation of Second CART Programme
for Major Pharmaceutical Company
Oxford, UK - 29 January 2016: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, announces today that the Group has initiated work on
a second Chimeric Antigen Receptor T cell (CART) programme for an
undisclosed indication. Under an agreement signed with Novartis in
October 2014, Oxford BioMedica will undertake process development
and manufacturing for the lentiviral vector associated with the new
programme.
Oxford BioMedica is currently manufacturing lentiviral vector
expressing CTL019 for Novartis and carrying out process development
work to establish the next-generation manufacturing process. The
Group also granted Novartis a non-exclusive licence in oncology
under the Group's LentiVector(R) platform and an exclusive licence
for the worldwide development and commercialisation of all CART
cell products arising from the process development collaboration.
In return, Oxford BioMedica will receive undisclosed royalties on
potential future sales of CART products covered by the
agreement.
Commenting on the announcement, John Dawson, Chief Executive
Officer of Oxford BioMedica, said: "We are excited to be providing
Novartis with the licence, process development and manufacturing
that they require for CTL019 and now for a second CART programme.
Oxford BioMedica is recognised as a world leader in the field of
lentiviral vectors and we are delighted to be supporting clinical
programmes where the need for this type of medical intervention is
vital."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Group's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Group has licenced products
and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich,
Biogen Idec, Emergent BioSolutions and ImaginAb. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUMCGUPQPUR
(END) Dow Jones Newswires
January 29, 2016 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024